Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1155/2017/1757940 http://scihub22266oqcxt.onion/10.1155/2017/1757940 C5467295!5467295 !28630858     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\28630858 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Biomed+Res+Int 2017 ; 2017 (ä): 1757940 Nephropedia Template TP {{tp|p=28630858 |t=2017. Pulsed Vincristine Therapy in Steroid-Resistant Nephrotic Syndrome |pdf=|usr=}}{{28630858 }} gab.com Text Pulsed Vincristine Therapy in Steroid-Resistant Nephrotic Syndrome JO: Biomed Res Int http://www.kidney.de/pget.php?&tw=1&pmid=28630858 #FOAvip Steroid-resistant nephrotic syndrome (SRNS) poses a therapeutic challenge for the paediatric nephrologist. As relentless progression to renal failure occurs with continued proteinuria, such patients will be treated with different cytotoxic medications with variable success rates and side-effects. We present here our findings on administering the anticancer drug vincristine for SRNS patients at a single centre in Sri Lanka. Methods. Between 2002 and 2007, fifty-four children presenting with steroid and cyclophosphamide resistance were treated with vincristine at 1.5?mg/m(2) in weekly intravenous pulses for 8 weeks along with a tapering steroid regimen of 6 months. All patients were closely followed up for 5 years. Results. Of the 54 patients 39 were males and 15 were females (age range 3.5-11.6 years, median 6.1 years). At the end of the treatment course, 21 patients achieved complete remission while 7 had partial remission and no response was seen in 26 patients. Sustained remission at 6, 12, 24, and 60 months were 15 (27.78%), 11 (20.37%), 9 (16.67%), and 7 (12.96%), respectively. Most side-effects observed were reversible and no serious side-effects were noted during vincristine therapy. Conclusion. Although its therapeutic mechanisms in nephrotic syndrome are still not elucidated, vincristine appears to be a potent alternative that could be considered for treating SRNS. Twit Text FOAVip Pulsed Vincristine Therapy in Steroid-Resistant Nephrotic Syndrome ????Biomed Res Int http://www.kidney.de/pget.php?&tw=1&pmid=28630858 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28630858 #FOAvip English Wikipedia <ref>{{Cite pmid|28630858 }}</ref> Pulsed Vincristine Therapy in Steroid-Resistant Nephrotic Syndrome #MMPMID28630858 Thalgahagoda S ; Abeyagunawardena S ; Jayaweera H ; Karunadasa UI ; Abeyagunawardena AS Biomed Res Int 2017[]; 2017 (ä): 1757940 PMID28630858 show ga Steroid-resistant nephrotic syndrome (SRNS) poses a therapeutic challenge for the paediatric nephrologist. As relentless progression to renal failure occurs with continued proteinuria, such patients will be treated with different cytotoxic medications with variable success rates and side-effects. We present here our findings on administering the anticancer drug vincristine for SRNS patients at a single centre in Sri Lanka. Methods. Between 2002 and 2007, fifty-four children presenting with steroid and cyclophosphamide resistance were treated with vincristine at 1.5?mg/m(2) in weekly intravenous pulses for 8 weeks along with a tapering steroid regimen of 6 months. All patients were closely followed up for 5 years. Results. Of the 54 patients 39 were males and 15 were females (age range 3.5-11.6 years, median 6.1 years). At the end of the treatment course, 21 patients achieved complete remission while 7 had partial remission and no response was seen in 26 patients. Sustained remission at 6, 12, 24, and 60 months were 15 (27.78%), 11 (20.37%), 9 (16.67%), and 7 (12.96%), respectively. Most side-effects observed were reversible and no serious side-effects were noted during vincristine therapy. Conclusion. Although its therapeutic mechanisms in nephrotic syndrome are still not elucidated, vincristine appears to be a potent alternative that could be considered for treating SRNS. |*Prednisolone [MESH] |Child [MESH] |Child, Preschool [MESH] |Drug Resistance/*drug effects [MESH] |Female [MESH] |Humans [MESH] |Male [MESH] |Nephrotic Syndrome/*drug therapy/pathology/physiopathology [MESH] |Remission Induction [MESH] |Retrospective Studies [MESH]Pulsed Vincristine Therapy in Steroid-Resistant Nephrotic Syndrome (epmc).pdf DeepDyve Pubget Overpricing